Hologic to Acquire Breast Surgical Guidance Company Endomagnetics for $310M

Hologic has signed a definitive agreement to acquire Endomagnetics (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million. Based in Cambridge, UK, Endomag develops and sells breast surgery localization and lymphatic tracing technologies, including the Magseed® marker for magnetic tissue localization before surgery, the Magtrace® lymphatic tracing injectable for breast cancer staging and the Sentimag® platform, which supports both localization and lymphatic tracing.

Endomag was founded in 2007 out of research conducted at the University College London (UCL) and the University of Houston, with revenues of $35 million in 2023. Endomag’s suite of solutions complements our existing breast surgery portfolio and will provide surgeons and radiologists with an expanded range of options to meet the individual needs of more breast cancer patients,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic.

To view the source version, please click HERE.

en_GBEnglish (UK)